- Irritable Bowel Syndrome - Constipation
- Irritable Bowel Syndrome - Diarrhea
- Others
Irritable bowel syndrome Market size was valued at USD 1.5 billion in 2022 and is poised to grow at a significant CAGR of 10.1% from 2023-2029.Gastrointestinal tract disorder characterized by stomach pain and alteration bowel habits. It hampers the regular development of intestinal muscle linings to move food along the tract. Based on the manifestations, the disorder can be mild to severe irritable bowel syndrome. The symptoms may include cramping, stomach torment, swelling and gas, mucus in the stool, constipation, and loose bowels. The exact reason for irritable bowel disease is not known however, it is related with increased awareness of body function, and unusual gastrointestinal tract movements. The diagnostic is performed by testing the stool and blood. Endoscopic procedures are also used in diagnosis of the syndrome. For instance, in March 2017, Astellas Pharma Inc. has launched LINZESS tablets, a guanylate cyclase receptor agonist to treat irritable bowel syndrome with constipation into Japan market. Europe market anticipated to have the notable growth rate owing to presence of the major market players and active development of drugs to treat the irritable bowel syndrome.
Global Irritable Bowel Syndrome Drugs Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
10.1%
Largest Market
North America
Fastest Growing Market
Asia-Pacific
Irritable Bowel Syndrome Drugs Market Dynamics
Global irritable bowel syndrome is primarily driven by the increase in prevalence of the syndrome worldwide. In addition robust pipeline of drugs such as alizyme, ramosetron and activity of the market players including product launches and collaborations projected to boost the market growth over the forecast period. Furthermore, change in the lifestyles, increased stress and favorable reimbursement policies in treatment of the disease projected to bolster the market share. Moreover, developments healthcare diagnostic sector in identifying the underlying disease and better understanding of pathology of disease projected to positively impact the development of new drug treatments. However, high cost of development and stringent regulatory policies are expected to hamper the market growth over the forecast period.
North-America Got Significant Share
Irritable Bowel Syndrome Drugs Market Regional Analysis
Geographically, global irritable bowel syndrome market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America irritable bowel syndrome market is projected to have the significant growth over the forecast period owing to the high prevalence rates of syndrome coupled with the well-established healthcare infrastructure and awareness in public related to syndrome. According to the Center for Disease Control and prevention (CDC), an estimated 3 million adults were diagnosed with irritable bowel syndrome in 2015. Asia Pacific market expected to gain the lucrative opportunity for growth owing to the development in healthcare infrastructure and huge base of patient pool. Market players in Asia Pacific region are adopting the strategies such as collaboration, new product launches and expansion to strengthen its position. For instance, in March 2017, Astellas Pharma Inc. has launched LINZESS tablets, a guanylate cyclase receptor agonist to treat irritable bowel syndrome with constipation into Japan market. Europe market anticipated to have the notable growth rate owing to presence of the major market players and active development of drugs to treat the irritable bowel syndrome.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- In April 2017, Takeda Pharmaceutical Company Limited and Finch Therapeutics has entered into the collaboration agreement to develop the microbiome therapeutics in inflammatory bowel disease
Global Irritable Bowel Syndrome Drugs Market Segmentation
By Condition
By Drug
- Alosetron
- Eluxadoline
- Linaclotide
- Lubiprostone
- Others
By Distribution Channel
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
By Geography
North America
- US
- Canada
Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Poland
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia & New Zealand
- ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Venezuela
- Rest of Latin America
Middle East and Africa (MEA)
- Gulf Cooperation Council (GCC) Countries
- Israel
- South Africa
- Rest of MEA
Frequently Asked Questions
The key segments covered in the Irritable Bowel Syndrome Drugs Market are technology, components, application, and end-users.
The Irritable Bowel Syndrome Drugs Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Irritable Bowel Syndrome Drugs Market key players are Allergan Plc. (Ireland), Lexicon Pharmaceuticals, Inc. (U.S.), Sucampo Pharmaceuticals (U.S.), Astellas Pharma Inc., Pfizer Inc. (U.S.), Novartis AG (Switzerland), Ironwood Pharmaceuticals, Inc. (U.S.), Synergy Pharmaceuticals (U.S.), Ono Pharmaceutical Co., Ltd. (Japan), Abbot Laboratories. (U.S.), Takeda Pharmaceutical Company Ltd. (Japan)
| 1.Executive Summary |
| 2.Global Irritable Bowel Syndrome Drugs Market Introduction |
| 2.1.Global Irritable Bowel Syndrome Drugs Market - Taxonomy |
| 2.2.Global Irritable Bowel Syndrome Drugs Market - Definitions |
| 2.2.1.Condition |
| 2.2.2.Drug |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Irritable Bowel Syndrome Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Irritable Bowel Syndrome Drugs Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Irritable Bowel Syndrome Drugs Market By Condition, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Irritable Bowel Syndrome - Constipation |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Irritable Bowel Syndrome - Diarrhea |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6.Global Irritable Bowel Syndrome Drugs Market By Drug, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Alosetron |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Eluxadoline |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Linaclotide |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Lubiprostone |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Irritable Bowel Syndrome Drugs Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Retail Pharmacies |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Online Pharmacies |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Hospital Pharmacies |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Irritable Bowel Syndrome Drugs Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Irritable Bowel Syndrome Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Condition Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Irritable Bowel Syndrome - Constipation |
| 9.1.2.Irritable Bowel Syndrome - Diarrhea |
| 9.1.3.Others |
| 9.2. Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Alosetron |
| 9.2.2.Eluxadoline |
| 9.2.3.Linaclotide |
| 9.2.4.Lubiprostone |
| 9.2.5.Others |
| 9.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Retail Pharmacies |
| 9.3.2.Online Pharmacies |
| 9.3.3.Hospital Pharmacies |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Irritable Bowel Syndrome Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Condition Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Irritable Bowel Syndrome - Constipation |
| 10.1.2.Irritable Bowel Syndrome - Diarrhea |
| 10.1.3.Others |
| 10.2. Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Alosetron |
| 10.2.2.Eluxadoline |
| 10.2.3.Linaclotide |
| 10.2.4.Lubiprostone |
| 10.2.5.Others |
| 10.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Retail Pharmacies |
| 10.3.2.Online Pharmacies |
| 10.3.3.Hospital Pharmacies |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11.Asia Pacific (APAC) Irritable Bowel Syndrome Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Condition Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Irritable Bowel Syndrome - Constipation |
| 11.1.2.Irritable Bowel Syndrome - Diarrhea |
| 11.1.3.Others |
| 11.2. Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Alosetron |
| 11.2.2.Eluxadoline |
| 11.2.3.Linaclotide |
| 11.2.4.Lubiprostone |
| 11.2.5.Others |
| 11.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Retail Pharmacies |
| 11.3.2.Online Pharmacies |
| 11.3.3.Hospital Pharmacies |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Irritable Bowel Syndrome Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Condition Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Irritable Bowel Syndrome - Constipation |
| 12.1.2.Irritable Bowel Syndrome - Diarrhea |
| 12.1.3.Others |
| 12.2. Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Alosetron |
| 12.2.2.Eluxadoline |
| 12.2.3.Linaclotide |
| 12.2.4.Lubiprostone |
| 12.2.5.Others |
| 12.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Retail Pharmacies |
| 12.3.2.Online Pharmacies |
| 12.3.3.Hospital Pharmacies |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Irritable Bowel Syndrome Drugs Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Condition Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Irritable Bowel Syndrome - Constipation |
| 13.1.2.Irritable Bowel Syndrome - Diarrhea |
| 13.1.3.Others |
| 13.2. Drug Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Alosetron |
| 13.2.2.Eluxadoline |
| 13.2.3.Linaclotide |
| 13.2.4.Lubiprostone |
| 13.2.5.Others |
| 13.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Retail Pharmacies |
| 13.3.2.Online Pharmacies |
| 13.3.3.Hospital Pharmacies |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Allergan Plc. (Ireland) |
| 14.2.2.Lexicon Pharmaceuticals, Inc. (U.S.) |
| 14.2.3.Sucampo Pharmaceuticals (U.S.) |
| 14.2.4.Astellas Pharma Inc. |
| 14.2.5.Pfizer Inc. (U.S.) |
| 14.2.6.Novartis AG (Switzerland) |
| 14.2.7.Ironwood Pharmaceuticals, Inc. (U.S.) |
| 14.2.8.Synergy Pharmaceuticals (U.S.) |
| 14.2.9.Ono Pharmaceutical Co., Ltd. (Japan) |
| 14.2.10.Abbot Laboratories. (U.S.) |
| 14.2.11.Takeda Pharmaceutical Company Ltd. (Japan) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Allergan Plc. (Ireland)
- Lexicon Pharmaceuticals, Inc. (U.S.)
- Sucampo Pharmaceuticals (U.S.)
- Astellas Pharma Inc.
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- Ironwood Pharmaceuticals, Inc. (U.S.)
- Synergy Pharmaceuticals (U.S.)
- Ono Pharmaceutical Co., Ltd. (Japan)
- Abbot Laboratories. (U.S.)
- Takeda Pharmaceutical Company Ltd. (Japan)